Want to stay smart? Sign up for a FREE 7-day trial today!
Spoon Feed —
The two-bag method of treating DKA was superior for both adult and pediatric patients in this systematic review and meta-analysis.
Source
Two-bag Versus One-bag Method for Adult and Pediatric Diabetic Ketoacidosis Management. Ann Emerg Med. 2025 Sep 6:S0196-0644(25)01095-9. doi: 10.1016/j.annemergmed.2025.07.032. Epub ahead of print. PMID: 40913602.
Spoon Feed —
This American Diabetes Association (ADA) consensus report addresses how to improve screening and early intervention for metabolic-dysfunction-associated steatotic liver disease (MASLD) in patients with prediabetes or type 2 diabetes.
Source
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025 Jul 1;48(7):1057-1082. doi: 10.2337/dci24-0094. PMID: 40434108
Spoon Feed —
Glucagon-like peptide-1 receptor agonists (GLP1 agonists) are not conclusively linked to an increased risk of thyroid cancer in observational trials.
Source
Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study. Diabetes Care. 2025 Jun 4:dc250154. doi: 10.2337/dc25-0154. Epub ahead of print. PMID: 40465422
Spoon Feed —
GLP-1 receptor antagonists likely increase the risk of cholelithiasis and GERD when compared to placebo, but this meta-analysis of RCTs suggests that the risk of pancreatitis, cholecystitis, and intestinal obstruction may be lower than previous studies.
Source
Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis. Gastroenterology. 2025 Jun 9:S0016-5085(25)00845-5. doi: 10.1053/j.gastro.2025.06.003. Epub ahead of print. PMID: 40499738
Spoon Feed —
Oral semaglutide decreased major adverse cardiovascular events in patients with diabetes and cardiac comorbidities.
Source
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025 May 29;392(20):2001-2012. doi: 10.1056/NEJMoa2501006. Epub 2025 Mar 29. PMID: 40162642
Spoon Feed —
In a 13-week randomized controlled trial (RCT) involving adults with insulin-treated type 2 diabetes (T2DM), automated insulin delivery (AID) was associated with a greater reduction in hemoglobin A1c (HbA1c) than intermittent insulin delivery.
Source
A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes. N Engl J Med. 2025 May 8;392(18):1801-1812. doi: 10.1056/NEJMoa2415948. Epub 2025 Mar 19. PMID: 40105270
Spoon Feed —
For the treatment of obesity in non-diabetic adults, tirzepatide was superior to semaglutide in both body weight reduction (20.2% tirzepatide vs 13.7% semaglutide) and waist circumference.
Source
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025 May 11. doi: 10.1056/NEJMoa2416394. Epub ahead of print. PMID: 40353578
Spoon Feed —
GLP1 agonist use was associated with better pancreatitis outcomes in a retrospective study of patients with type 2 diabetes.
Source
Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis. Am J Gastroenterol. 2025 May 13. doi: 10.14309/ajg.0000000000003525. Epub ahead of print. PMID: 40358430
Spoon Feed —
In the GRADE RCT, poor glycemic control was associated with worse cognitive scores in patients with type 2 diabetes. However, none of the investigated treatments showed a superior effect on cognitive scores, despite insulin glargine and liraglutide offering better glycemic control.
Source
Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes: The GRADE Randomized Clinical Trial. JAMA Intern Med. 2025 May 19:e251189. doi: 10.1001/jamainternmed.2025.1189. Epub ahead of print. PMID: 40388190
Spoon Feed —
Even with infrequent administration, zoledronic acid effectively prevented morphometric vertebral fracture in early postmenopausal women.
Source
Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age. N Engl J Med. 2025 Jan 16;392(3):239-248. doi: 10.1056/NEJMoa2407031. PMID: 39813642